Endocrine Abstracts

Objective: Analyse possible effects on physical examination, blood count, liver and kidney function, and steroidogenic hormones synthesis. Know the satisfaction of patients with the first injectable treatment for hypercholesterolemia approved in our country.

Material and methods: Data were collected from patients with heterozygous familial hypercholesterolemia treated with PCSK9 inhibitors. Clinical, physical and analytical data were collected at baseline, 1 month and 3 months. Satisfaction test (TQ21M-9) was performed 3 months after treatment.

Results: Data were obtained from 13 patients, 45.5% male. Mean age: 49.5 years (26-74). Mean pre and postreatment levels were: TC: 243.8±27.7 vs 148.5±47.4 mg/dl (P 0.01), LDL-C: 159±23.9 vs 69.9±39.3 (P 0.01), non-HDL-C 185.3±21.5 vs 91.8±32.7 (P 0.01), Apo B 136±19.9 vs 64.3±11.04 (P 0.01), lipoprotein (a) 133.1±9.9 vs 112.5±5.1 (P 0.04). HbA1c 5.9±0.4 vs 5.70.3 (NS), creatinine 1.01±0.3 vs 0.92±0.2 (NS), GOT 34.7±34.2 vs 34.6±21.9 (NS), GPT 29.8±18.7 vs 28.2±13.9 (NS). Weight: 70.9±11.2 vs 73.5±11 kg (NS). No effects were detected in blood count, systolic, diastolic BP or heart rate. The mean levels of hormones were: Testosterone 4.3±1.4 vs 4.04±1.8 ng/ml (NS), TSH 2.2±0.8 vs 2.14±0.8 mU/l (NS), T4l 16.3±1.1 vs 14.8±0.4 (NS) ACTH 24.2±17.7 vs 30.2±25.2 (NS), Cortisol 14±2.9 vs 16.6±2.1 (NS) Vitamin D3 41.5±49.1±18.2 ng/ml (NS). Patients showed a high level of satisfaction with treatment, with mean scores of 75.9% for effectiveness items, 80.2% convenience items and 85.2% overall satisfaction.

Conclusion: Despite the decrease in TC and LDL C levels, there were no significant changes in the levels of stereogenic hormones or vitamin D levels. Treatment with PCSK9 inhibitors did not change hemogram, hydrocarbon metabolism, kidney, liver function, or physical examination parameters. Patients show a high satisfaction with this injectable treatment for hypercholesterolemia.